The National Drug Abuse Treatment Clinical Trials Network (U10)

国家药物滥用治疗临床试验网络 (U10)

基本信息

批准号：
8432961
负责人：
KATHLEEN M. CARROLL
金额：
$ 56.09万
依托单位：
MCLEAN HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2002
资助国家：
美国
起止时间：
2002-09-30 至 2015-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8432961
关键词：
Adolescent Adopted Area Attention deficit hyperactivity disorder Behavior Therapy Buprenorphine Clinical Trials Network Collaborations Communities Consult Counseling Dental Clinics Development Doctor of Medicine Doctor of Philosophy Drug abuse Environment Evidence based practice Faculty Funding Genetic Geography Heterogeneity Hour Human Resources Individual Intervention Lead Leadership Master of Public Health Medical Mission Monitor National Institute of Drug Abuse New England Opiate Addiction Opioid Paper Patients Performance Pharmaceutical Preparations Pharmacotherapy Positioning Attribute Primary Health Care Process Productivity Professional counselor Protocols documentation Psychotherapy Publications Recording of previous events Research Research Personnel Resources Rural Site Smoker Structure Technology Transfer Testing Therapeutic Studies Training Universities addiction base clinically relevant cost effectiveness design flexibility improved interest medical specialties meetings member neuroimaging patient population peer prescription opioid public health relevance research and development suburb treatment program

项目摘要

DESCRIPTION (provided by applicant): This competing renewal application represents the merger of two of the most productive nodes of the NIDA Clinical Trials Network - the New England Node, led by Yale University's Kathleen Carroll, Ph.D., and the Northern New England Node, led by Harvard University's Roger Weiss, M.D.- to form the New England Consortium Node (NECN). Drs. Carroll and Weiss will both be PIs of the NECN, using the multiple PI mechanism. This proposal to combine these two nodes enhances the strengths of each node by providing broader and deeper scientific expertise and greater diversity of community treatment programs (CTPs). Beyond capitalizing on economies of scale for prudent use of CTN resources, our nodes provide an ideal opportunity for integration, based on 1) geographical proximity, 2) complementary scientific expertise, 3) a history of collaboration, and 4) complementary CTP patient populations. Since joining the CTN, the New England and Northern NE Nodes have been highly productive in all key areas of CTN performance: 1) trial leadership, 2) scientific productivity, including publications and presentations, 3) administrative leadership, 4) excellent trial performance, and 5) dissemination of findings from CTN trials to CTPs. NECN personnel have led 4 highly successful and productive CTN trials and have been leaders in disseminating findings of CTN-tested interventions to the wider drug abuse treatment community, both in New England and nationally. Administrative leadership is exemplified by election by our CTN peers to virtually all major CTN leadership positions. NECN CTPs have adopted a number of evidence- based practices, and have themselves disseminated information about these practices regionally, nationally, and internationally. This proposal highlights the accomplishments of the New England and Northern NE Nodes in their current funding periods and their entire tenure in the CTN. The proposal also describes plans for integration of these two highly successful nodes into a seamlessly integrated combined node. Finally, the proposal will use a number of potential research ideas that are consistent with the evolving mission of the CTN. PUBLIC HEALTH RELEVANCE: The CTN does clinically relevant drug abuse research in real-world settings; the structure of the CTN is designed to maximize the likelihood that treatments found to be successful in CTN trials are then disseminated widely to CTPs nationally, which should help improve the overall treatment of drug abuse and comorbid conditions nationwide.

描述（由申请人提供）：这一竞争性更新申请代表了 NIDA 临床试验网络中两个最具生产力的节点的合并——由耶鲁大学 Kathleen Carroll 博士领导的新英格兰节点和新英格兰北部节点的合并。 Node 由哈佛大学医学博士 Roger Weiss 领导，组建新英格兰联盟节点 (NECN)。博士。 Carroll 和 Weiss 都将成为 NECN 的 PI，采用多重 PI 机制。这项结合这两个节点的提议通过提供更广泛、更深入的科学专业知识和更多样化的社区治疗计划 (CTP) 来增强每个节点的优势。除了利用规模经济谨慎使用 CTN 资源之外，我们的节点还提供了理想的整合机会，基于 1) 地理位置接近，2) 互补的科学专业知识，3) 合作历史，以及 4) 互补的 CTP 患者群体。自加入 CTN 以来，新英格兰和北东北节点在 CTN 绩效的所有关键领域都表现出色：1) 试验领导力，2) 科学生产力，包括出版物和演示，3) 行政领导，4) 出色的试验表现， 5) 将 CTN 试验的结果传播给 CTP。 NECN 人员领导了 4 项非常成功且富有成效的 CTN 试验，并在向新英格兰和全国更广泛的药物滥用治疗社区传播经过 CTN 测试的干预措施的结果方面发挥了带头作用。行政领导的例子是我们的 CTN 同行选举几乎所有主要的 CTN 领导职位。 NECN CTP 采用了许多基于证据的做法，并自行在区域、国家和国际范围内传播有关这些做法的信息。该提案强调了新英格兰和北东北节点在当前资助期间以及在 CTN 的整个任期内所取得的成就。该提案还描述了将这两个非常成功的节点集成为无缝集成组合节点的计划。最后，该提案将使用一些与 CTN 不断发展的使命相一致的潜在研究想法。公共卫生相关性：CTN 在现实环境中进行临床相关的药物滥用研究； CTN 的结构旨在最大限度地提高 CTN 试验中成功的治疗方法在全国范围内广泛传播给 CTP 的可能性，这将有助于改善全国范围内药物滥用和合并症的整体治疗。